TRPM2 and cancer: In Jurkat lymphohematopoietic cancer cells, stably expressing apoptosis-resistant Bcl-2, treatment with N-(p-amylcinnamoyl) anthranilic acid (ACA), a TRPM2 inhibitor, followed by irradiation (IR), reduced the CAMKII phosphorylation and hampered the radiation-assisted inactivation of cdc2, which is dependent on the indicated phosphorylation (233).